Korean J Gastroenterol.  2009 May;53(5):329-330. 10.4166/kjg.2009.53.5.329.

Treatment of Hepatitis B Virus Resistant to Lamivudine and Adefovir

• Kim JW

• KMID: 1767700
• DOI: http://doi.org/10.4166/kjg.2009.53.5.329

Abstract

No abstract available.

MeSH Terms

Adenine/*analogs & derivatives/therapeutic use
Antiviral Agents/*therapeutic use
DNA, Viral/analysis
Drug Resistance, Viral
Drug Therapy, Combination
Hepatitis B, Chronic/*drug therapy
Humans
Lamivudine/*therapeutic use
Phosphonic Acids/*therapeutic use

Reference

1. Lok AS, Lai CL, Leung N, et al. Longterm safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003; 125:1714–1722.

2. Lee KS, Kim DJ. Management of chronic hepatitis B. Korean J Hepatol. 2007; 13:447–488.

3. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007; 45:307–313.

4. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007; 133:1445–1451.

5. Suh HJ, Park MK, Lee HI, et al. Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis B patients with resistnace to lamivudine and adefovir consecutively. Korean J Gastroenterol. 2009; 53:305–310.

6. Kwon HC, Cheong JY, Cho SW, et al. Emergence of adefo-vir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol. 2009; 24:49–54.

7. Zaaijer HL, Takkenberg RB, Weegink CJ, et al. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir. J Med Virol. 2009; 81:413–416.